Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.

Journal of neural transmission (Vienna, Austria : 1996) - 1 May 2017

Lidö Helga Höifödt, Jonsson Susanne, Hyytiä Petri, Ericson Mia, Söderpalm Bo

Abstract excerpt

The glycine transporter-1 inhibitor Org25935 is a promising candidate in a treatment concept for alcohol use disorder targeting the glycine system. Org25935 inhibits ethanol-induced dopamine elevation in brain reward regions and reduces ethanol intake in Wistar rats. This study aimed to further characterise the compound and used ethanol consumption, behavioral measures, and gene expression as parameters to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Drinking
Share to Central Nervous System Depressants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Choice Behavior

Share to Dose-Response Relationship, Drug

Share to Ethanol

Share to Motor Activity

Share to Neurotransmitter Agents

Share to Rats, Wistar

Source

Open in PubMed Open full text

Identifiers

PMID: 28161754
DOI: 10.1007/s00702-017-1685-z
PMCID: PMC5399095

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.PMID 28161754Read ↗

Current Pharmacotherapies for Alcohol Use Disorder in Italy: From Neurobiological Targets to Clinical PracticeSemantic proximity Read ↗

Pharmacotherapy for alcohol dependence: A stratified approach.Semantic proximity Read ↗

Pharmacogenetic approaches to the treatment of alcohol addiction.Semantic proximity Read ↗

Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.Semantic proximity Read ↗

Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1Semantic proximity Read ↗

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction.Semantic proximity Read ↗

Pharmacotherapy, Pharmacogenomics, and The Future of Alcohol Dependence Treatment, Part 2Semantic proximity Read ↗

Behavioral characterization of knockin mice with mutations M287L and Q266I in the glycine receptor α1 subunit.Semantic proximity Read ↗

Antagonism of GluK1-containing Kainate Receptors Reduces Ethanol Consumption by Modulating Ethanol Reward and WithdrawalSemantic proximity Read ↗

Glycine receptors containing α2 or α3 subunits regulate specific ethanol-mediated behaviors.Semantic proximity Read ↗

The FDA-approved drug apremilast suppresses alcohol intake: clinical and pre-clinical validationSemantic proximity Read ↗

Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.